- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02778542
Bidirectional Text Messaging for Measurement and Motivation of Medication Adherence in Hypertension, a Pilot Study (Way2Text)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The goal of this pilot study is to test different approaches to monitor medication adherence in hypertension patients, leveraging the NIH-funded Way to Health platform. Patients with poor blood pressure control will be recruited from the University of Pennsylvania Health System and offered remote monitoring with electronic pill bottles or bidirectional text messaging. Our aim is to analyze and compare the effects of remote monitoring with electronic pill bottles versus bidirectional messaging on blood pressure reduction after 4 months.
Patients will be randomized 2:2:1 to Arm A (electronic pill bottle), Arm B (bidirectional messaging), and Arm C (usual care). A total of 150 participants will be enrolled in the study, with 60 in each intervention arm and 30 in the control. After 4 months all patients will complete an in-person follow-up blood pressure measurement and end of program survey. We will monitor all patient's medical records for an additional 8 months after the intervention to track blood pressure measurement and number of outpatient visits.
Accrual: Participants in this study will be patients being treated within the UPHS health system. They will be identified via daily electronic medical records review by our study staff. The study staff will work with UPHS to create a filter for the electronic medical record system that will generate a monthly list of patients who may meet the study criteria. A study coordinator will review the list of patients to determine eligibility. If patients meet the minimal requirements they will be added to the study screening data base and contacted via recruitment letter and up to 3 follow-up phone calls. The intervention of the study will be 4 months from date of consent, and an additional 8 months of follow-up, passively monitoring visit utilization and blood pressure in the electronic medical record. After a patient enrolls a message will be sent to their PCP via EPIC to notify their physician that their patient is enrolled in our study. At the conclusion of the intervention, participants will complete an in-person blood pressure measurement and post-study survey. Information about BP measurements will be recorded in EPIC and message will be sent to the PCP with the research BP measurement included.
Analysis Plan: The primary outcome will be the systolic blood pressure during the 4 month visit, controlling for the initial systolic blood pressure. Additional outcomes include, percent that are normotensive, recruitment and attrition rates, and patient perceptions about intervention from survey. We will also track BP measurements from the EMR that is obtained through usual care as well as utilization of PCP visits, MPM messaging, and phone calls. We will also compare medication adherence between patients with the electron pill bottles and the patients with bidirectional messaging. Assuming 5.3mmHg standard deviation of SBP (given variability of BP over time) and a two-sided significance level of 0.017 (to accommodate the three pairwise comparisons), our sample size of 60 in each intervention arm and 30 in the control arm provides 80% power to detect a difference in SBP reduction of 3.75 mmHg between either intervention and usual care, and a difference in SBP reduction of 3.1 mmHg between the electronic pill bottle and bidirectional text messaging arms.
Data Safety: Paper-based records will be kept in a secure location and only be accessible to personnel involved in the study. Computer-based files will only be made available to personnel involved in the study through the use of access privileges and passwords.
Prior to access to any study-related information, personnel will be required to sign statements agreeing to protect the security and confidentiality of identifiable information.
Wherever feasible, identifiers will be removed from study-related information. Precautions are in place to ensure the data is secure by using passwords and encryption, because the research involves web-based surveys.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hypertension patients aged 18-75
- At least two clinic visits in the past 12 months
- Blood pressure readings in the last two visits that exceed recommended guidelines (150/90 or 140/90 if aged 21-59 yrs. or with diabetes or nondiabetic CKD).
- Cellular phone with text messaging capabilities
- Prescribed at least one medication for hypertension
Exclusion Criteria:
- Will not or cannot give consent
- Diagnosed with dementia, end stage renal disease, cirrhosis, or metastatic cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Electronic Pill Bottle
Participants will be mailed an electronic pill bottle for their blood pressure medication.These pill bottles will track how often the participant opens the bottle to take their medication and will transmit that information to study team via cellular data.
Participants will also receive a daily text message reminder to take your blood pressure medication.
|
Patients receive electronic pill bottle for their blood pressure medication.
Study team can monitor pill bottle openings.
Patients also receive daily text reminders to take their blood pressure medication.
|
Active Comparator: Bidirectional Text Messaging
Participants assigned to bi-directional texting, will receive a daily text message reminder to take their blood pressure medication.
Patients in this arm are expected to send a response to the reminder message, indicating if they took their medication that day.
|
Patients receive daily text reminders to take their blood pressure medication.
Patients are asked to text their adherence daily.
|
No Intervention: Usual Care
Participants in this arm do not receive a medication reminder system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systolic blood pressure
Time Frame: after 4 month intervention
|
The primary outcome will be the systolic blood pressure during the 4 month in-person visit, controlling for the initial systolic blood pressure
|
after 4 month intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medication Adherence
Time Frame: 4 month intervention
|
We will compare medication adherence between patients with the electronic pill bottles and the patients with bidirectional messaging.
|
4 month intervention
|
Passive EMR monitoring
Time Frame: 12 months, including 4 months of intervention and 8 months after intervention
|
We will also track BP measurements from the EMR that is obtained through usual care as well as utilization of PCP visits, MPM messaging, and phone calls.
|
12 months, including 4 months of intervention and 8 months after intervention
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 824815
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Electronic Pill Bottle
-
Massachusetts General HospitalNational Multiple Sclerosis Society; Pillsy, Inc.CompletedElectronic Pill Bottle Monitoring to Promote Medication Adherence for People With Multiple SclerosisMultiple SclerosisUnited States
-
University of PennsylvaniaCompletedPatients With Principal or Secondary Diagnosis Code of Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410 (Except When 5th Digit Was 2)United States
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...Completed
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University of PennsylvaniaMerck Sharp & Dohme LLCCompletedDiabetes | Medication Adherence | High Blood PressureUnited States
-
University of PennsylvaniaCompletedAcute Myocardial Infarction (AMI)United States
-
University of PennsylvaniaMerck Sharp & Dohme LLCCompletedDiabetes | Medication Adherence | High Blood PressureUnited States
-
Manan ShuklaCompletedAsthma | Chronic DiseaseUnited States
-
University of WashingtonUniversity of California, Los Angeles; Dana-Farber Cancer InstituteCompletedMedication Adherence
-
University of PennsylvaniaCompleted